Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs (cDMARDs), such as methotrexate. For patients who fail cDMARD treatment, or exhibit an inadequate response, the U.S. market is crowded with efficacious biologics and targeted oral therapies, including blockbuster TNF-alpha inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) as well as non-TNF-alpha inhibitors such as BMS’s Orencia and Roche’s Actemra, and the oral JAK inhibitors, Xeljanz (Pfizer), Olumiant (Eli Lilly), and Rinvoq (AbbVie). Indeed, the FDA approval of Rinvoq has increased competition within the JAK class and among the non-TNF biologics, and has further expanded physicians’ treatment armamentarium.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Amgen, Biogen, BMS, Eli Lilly, Janssen, Pfizer, Roche, Regeneron, Sanofi, UCB.
Key drugs: Actemra, biosimilar infliximab, Cimzia, Enbrel, Humira, Kevzara, Olumiant, Orencia, Remicade, Rinvoq, Rituxan, Simponi, Simponi Aria, Xeljanz.